> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-043.md).
# BRE 043
## Tumor-Specific RF Frequencies and Selective Cancer Suppression
**Clinical Cancer Names:** Hepatocellular Carcinoma and Breast Carcinoma
**Common Cancer Names:** Liver Cancer and Breast Cancer
## Source
Zimmerman, J. W., Jimenez, H., Pennison, M. J., Brezovich, I., Morgan, D., Mudry, A., Costa, F. P., Barbault, A., & Pasche, B. (2013).
*Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies.*
*Chinese Journal of Cancer, 32(11), 573–581.*
***
## BRS Score
**BRS:** 8.6 / 10\
**STEMD:** S8 / T9 / E8 / M8 / D10\
**External Evidence Level:** Moderate–High clinical translational evidence
## Score Interpretation
BRE-043 receives a strong score because it supports frequency-specific tumor targeting, tissue-specific electromagnetic sensitivity, tumor-selective signaling, mitotic disruption, migration suppression, invasion suppression, and minimal toxicity. Its strongest value is discovery and translational direction because it introduces tumor-specific frequency selection as a major organizing principle.
***
## Entry Summary
BRE-043 asks a major frequency-specific oncology question:
Can cancer types respond to specific electromagnetic frequency patterns?
This entry focuses on radiofrequency electromagnetic fields delivered through a 27.12 MHz RF carrier and amplitude-modulated at tumor-specific frequencies.
In simple language:
The study suggests that different cancers may respond to different signal patterns. Instead of treating all tumors with one general electromagnetic exposure, the signal may be matched to the cancer type.
***
## What BREXAtlas Found
BREXAtlas identifies this primary mechanism chain:
Tumor-specific frequency\
↓\
Electromagnetic signaling response\
↓\
Mitotic disruption\
↓\
Reduced proliferation\
↓\
Tumor suppression
The secondary chain is:
Tumor-specific frequency\
↓\
Migration pathway alteration\
↓\
Invasion suppression\
↓\
Reduced metastatic potential
This makes BRE-043 important because it strengthens one of the most important BREXAtlas ideas: frequency may matter by cancer type.
***
## Questions This BRE Helps Answer
What does “tumor-specific frequency” mean?
A tumor-specific frequency means an electromagnetic signal pattern selected for a particular tumor type.
What BREXAtlas found:\
BRE-043 supports that tumor-specific amplitude modulation produced tissue-specific biological responses.
What exposure system was used?
What BREXAtlas found:\
The extraction identifies a 27.12 MHz RF carrier, tumor-specific amplitude modulation frequencies, and intrabuccal RF administration.
Is this the same as TTFields?
What BREXAtlas found:\
No.
TTFields typically use lower-frequency alternating electric fields. BRE-043 focuses on RF electromagnetic fields amplitude-modulated at tumor-specific frequencies.
Both belong in bioelectric oncology, but they are different exposure systems.
Why does this matter for people affected by cancer?
If cancers respond differently to frequency patterns, future treatment design may need to become more personalized.
This entry does not prove that frequency-specific RF treatment is ready as a standard therapy. It does show that the question deserves organized study.
***
## Study Classification
| Category | Classification |
| ------------------------------------------ | ---------------------------------------------------------------------------------------- |
| Study Type | Clinical translational review |
| Tissue Category | Hepatocellular carcinoma; breast carcinoma; multi-tissue oncology |
| Common Cancer Names | Liver cancer; breast cancer |
| Exposure System | 27.12 MHz RF carrier; tumor-specific amplitude modulation; intrabuccal RF administration |
| Direct TTFields Evidence | No |
| Direct RF EMF Evidence | Yes |
| Frequency-Specific Evidence | Yes |
| Suitable for Frequency Index | Yes |
| Suitable for RF Oncology Index | Yes |
| Suitable for Multi-Tissue Comparison Index | Yes |
***
## Mechanisms
**MEC-002: Frequency Specificity**
BRE-043 supports the principle that tumor response may depend on specific electromagnetic frequency patterns.
**MEC-035: CACNA1H Electromagnetic Antenna Signaling**
BRE-043 connects conceptually to later calcium-channel antenna models, though this entry itself should be treated as frequency-specific RF oncology rather than direct CACNA1H proof.
**MEC-041: Pattern-Specific Electromagnetic Calcium Activation**
BRE-043 strengthens the pattern-specific electromagnetic response branch.
**MEC-101: Tumor-Specific RF Modulation**
Amplitude-modulated RF signals may produce tumor-type-specific biological effects.
**MEC-102: Tissue-Specific Electromagnetic Sensitivity**
Different tumor tissues may show different electromagnetic response profiles.
***
## Discoveries
**DISC-016: Voltage-Gated Calcium Antenna Systems**
BRE-043 connects conceptually to this discovery branch because frequency-specific responses may involve biological signal receivers, but the entry does not independently prove a specific calcium-channel mechanism.
**DISC-018: Time-Varying EMF Calcium-Channel Selectivity**
BRE-043 strengthens the broader idea that waveform and signal pattern can matter.
**DISC-028: Tumor-Specific Frequency Targeting**
BREXAtlas identifies this as a major discovery:
Cancer types may show tumor-specific responses to amplitude-modulated RF electromagnetic signals.
***
## Connections to Other BRE Entries
**Connected to BRE-030**
BRE-030 showed breast cancer brain metastasis response to AM RF EMF through CACNA1H/CaV3.2 calcium-channel signaling.
BRE-043 provides an earlier frequency-specific RF oncology foundation that supports the broader pathway.
**Connected to BRE-032**
BRE-032 showed time-varying EMF cancer suppression through T-type calcium channels.
BRE-043 supports the broader pattern that signal structure and frequency specificity matter.
**Connected to BRE-021**
BRE-021 emphasized frequency optimization across TTFields systems.
BRE-043 expands frequency optimization into RF amplitude-modulated oncology.
**Connected to BRE-033 and BRE-034**
BRE-033 and BRE-034 focused on liver cancer TTFields at 150 kHz.
BRE-043 includes hepatocellular carcinoma in a different frequency-specific RF system, creating a cross-platform liver cancer comparison point.
**Connected to BRE-041**
BRE-041 focused on targeted field amplification using ferroelectric nanoparticles.
BRE-043 focuses on targeted signal selection using tumor-specific amplitude modulation.
Together, they suggest two future precision directions: target the field physically and target the signal biologically.
***
## Research Gaps Identified
**RG-213: Tumor-Specific Frequency Validation Gap**
More independent validation is needed to confirm tumor-specific frequency effects across cancer types.
**RG-214: Mechanism Identification Gap**
More work is needed to determine which biological structures receive or translate tumor-specific RF signals.
**RG-215: RF Dosimetry Standardization Gap**
Future studies need standardized RF exposure, modulation, dose, duration, and delivery reporting.
**RG-216: Cross-Platform Comparison Gap**
Tumor-specific RF systems should be compared carefully with TTFields, ELF-EMF, and nanoparticle-assisted field systems.
**RG-217: Clinical Trial Expansion Gap**
More controlled clinical trials are needed before broad treatment conclusions can be made.
***
## Scientific Caution
BRE-043 supports tumor-specific RF oncology as a clinical translational concept, but the extraction does not establish a single definitive mechanism such as calcium-channel activation for all tumor-specific frequencies.
***
## Why This Entry Matters
For researchers, BRE-043 strengthens the frequency-specific branch of bioelectric oncology.
For patients and families, the simple idea is this:
Different cancers may respond to different electromagnetic signal patterns.
That does not mean this is a standard treatment yet. It means frequency matching may be an important future research direction.
***
## Entry Conclusion
BRE-043 is a major frequency-specific RF oncology entry.
BRE-021 established frequency optimization in TTFields.
BRE-030 and BRE-032 showed calcium-channel-linked electromagnetic response pathways.
BRE-043 adds tumor-specific amplitude-modulated RF signals as a separate but connected strategy.
The central question emerging from this entry is:
Can electromagnetic signals be matched to cancer type in the same way some drugs are matched to tumor biology?
For BREXAtlas, BRE-043 is essential because it supports the future Frequency Specificity Index across TTFields, RF EMF, calcium-channel systems, and precision bioelectric oncology.
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://www.brexatlas.org/bre-001/bre-043.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.